Sagimet's Partner Ascletis Reports Positive 52-Week Phase 3 Data for Denifanstat in Acne
Ascletis presented positive full 52-week results from Phase 3 open-label extension trial of denifanstat (ASC40-304) in moderate-to-severe acne at EADV 2026. Sagimet holds development rights outside China under a licensing agreement.
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
Ascletis completed and presented 52-week Phase 3 open-label extension data for denifanstat, a FASN inhibitor, in acne vulgaris patients at the European Academy of Dermatology and Venereology Congress in Vienna on September 30, 2026. Ascletis holds exclusive China rights; Sagimet retains rest-of-world rights.
Why it matters
Positive long-term safety and efficacy data from a Phase 3 extension trial strengthens the clinical profile for denifanstat's regulatory pathway. Extended follow-up data reduce uncertainty around durability of response and adverse event emergence, potentially supporting future regulatory submissions and commercialization timelines for both partners.
Market transmission
Favorable Phase 3 extension results improve probability of regulatory approval and market entry, supporting Sagimet's pipeline valuation and near-term catalysts. Ascletis' China approval pathway may accelerate, creating near-term revenue potential for Sagimet via milestone payments or royalties. Positive dermatology data may also broaden FASN inhibitor interest across metabolic and fibrotic indications.
What to watch
Regulatory filing timelines in China (Ascletis) and other regions (Sagimet); magnitude of efficacy/safety metrics disclosed; timing and geography of next clinical or regulatory announcements; any partnership expansion or financing activity by Sagimet.
Source:GlobeNewswire US
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.